Merck starts rolling FDA submission for its Ebola vaccine, aiming to finish next year

Merck’s late-stage Ebola vaccine has already been deployed against recent outbreaks in the Democratic Republic of Congo. Now, after years of development, the company is ready to seek FDA approval.